Mayne Pharma to invest $65 million in Greenville facility creating 110 jobs

Friday, Aug 28, 2015

Drug manufacturer Mayne Pharma will invest $65 million at its facility in Greenville and add 110 jobs in the next five years.

The Australian-based specialty pharmaceutical company develops and manufactures branded and generic products globally, in addition to providing contract development and manufacturing services. Its production portfolio includes aspirin, morphine and oxycodone. In 2014, the parent company recorded $143 million in revenue.

This announcement comes just one day after Novo Nordisk announced a major investment in Johnston County.

The Greenville facility started as Metrics Contract Services in 1994 before being acquired by Mayne Pharma in 2012, which is traded publicly on the Australian exchange under the symbol “MYX.” Expansion plans include 126,000 square feet of new FDA-compliant space for use in large-scale oral and solid-dose manufacturing.

The company currently employs 350 workers in Pitt County. The new positions will include scientists, quality assurance specialists, and manufacturing operators, just to name a few. Salaries will vary by position, but will average $60,000 per year. Pitt County’s overall annual wage is currently $35,154.

“Expanding our Greenville operations solidifies Mayne Pharma’s aspirations in the U.S. market, while building our talented workforce. Once operational, we can take on new and larger products, specifically those that rely upon our company’s drug-delivery and potent handling expertise,” said Stefan Cross, president of Mayne Pharma USA.